COX-2 Cardio Risk Is Class Effect, But Varies By Drug And Dose, Cmte. Says
This article was originally published in The Pink Sheet Daily
Executive Summary
While a COX-2 class signal is likely, several committee members suggest data are not conclusive enough to make a "global" statement on the class. Voting FDA consultant Nissen recommends FDA explore whether COX-2 inhibition plays a role in hypertension, thereby contributing to an increased cardiovascular risk.
You may also be interested in...
FDA Approves Santarus’ Zegerid As First PPI Immediate-Release Capsule
The company will highlight rapid absorption of Zegerid capsules over available delayed-release PPIs.
FDA Approves Santarus’ Zegerid As First PPI Immediate-Release Capsule
The company will highlight rapid absorption of Zegerid capsules over available delayed-release PPIs.
Efficacy Differences Within Drug Classes Unsupported By Data, FDA's Temple Says
Studies that look for differences in efficacy among members of the same drug class are only performed when necessary for approval, CDER Office of Medical Policy Director Temple tells DIA. While questioning the introduction of "follow-on" compounds, Temple also highlights AstraZeneca's success in achieving a more optimal dose for Nexium.